As the dust settles from last week's surprising announcement that an HIV vaccine combination may protect some people from the virus, scientists are talking about what else the vaccine trial might tell them. On 24 September, leaders of a US$119-million study of 16,000 people in Thailand reported that the combination of two shots had reduced the risk of HIV infection by one-third. Now, the vaccine's fate will depend on whether scientists can figure out its 'correlate of protection'. (source: nature.com)
|
